Disruptive Technologies Transforming Upstream Process Intensification for All Modalities

Disruptive Technologies Transforming Upstream Process Intensification for All Modalities

 

Disruptive Technologies Transforming Upstream Process Intensification for All Modalities

Accelerating the Future of Biopharmaceuticals with Cutting-Edge Perfusion Technology

How XCell® ATF is reshaping the landscape of biologics production across a variety of cell types and applications.

Dive into the heart of bioprocessing innovation with key insights:

  • Perfusion technology dramatically increases cell densities to over 200 million cells/mL with CHO cells.
  • Achieves a 3-5x improvement in viral yield in vaccine manufacturing using N and N-1 perfusion strategies.
  • The XCell® ATF System is globally recognized, with over 500 installations enhancing productivity in biomanufacturing.
  • Supports a wide range of molecules and cell types, proving its versatility and efficiency across the board.
  • Offers significant cost savings and reduced environmental footprint, contributing to more sustainable manufacturing practices.

Unlock the full potential of your biologics pipeline with our in-depth analysis on XCell® ATF technology. Download now.

White Paper from  accruent_logo

    Read the full content


    You have been directed to this site by Global IT Research. For more details on our information practices, please see our Privacy Policy, and by accessing this content you agree to our Terms of Use. You can unsubscribe at any time.

    If your Download does not start Automatically, Click Download Whitepaper

    Show More